Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around
50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing
countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues,
however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause
disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post
partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to
the virus.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. The
model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates.
LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine
mechanism of action and vaccinee serostatus.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 17.5%.
Please review the TERMS and CONDITIONS of purchase.
